12:00 AM
Jul 21, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Reolysin: Completed Phase II enrollment

Oncolytics said NIH’s NCI completed enrollment of 70 patients in the open-label, U.S. Phase II OSU-10045 trial comparing carboplatin and paclitaxel on day 1 plus IV Reolysin on days 1-5 of 21-day cycles vs....

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >